The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

According to the FDA, the drug is approved for people with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and those with the mild dementia stage of Alzheimer’s ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some ... a third of people living with dementia in the UK don’t get a diagnosis at all.

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

The recent FDA approval of Eli Lilly’s new immunotherapy ... Dr Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation (ADDF) described the latest ...

A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal, fell short in a randomized trial reported Tuesday afternoon. Athira Pharma said that Alzheimer ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.